SUBSCRIBE: Print / eNewsletter
BRAF/MEK Combo Improved Outcomes in Melanoma
Combining BRAF and MEK inhibitors resulted in better response, PFS, and overall survival compared with a BRAF inhibitor alone in BRAF-positive melanoma patients, according to results presented at the 2014 ESMO Congress.
FDA Approves Anti-PD-1 Drug for Advanced Melanoma
The FDA granted accelerated approval to pembrolizumab (Keytruda) for treating patients with advanced melanoma who are no longer responding to other drugs.
Flight Crews at Higher Risk for Melanoma
Pilots and cabin crews were found to have twice the incidence of melanoma and about 40% increased melanoma mortality compared with the general population.
Viagra Use Linked With Increased Risk for Melanoma
Men who used sildenafil (Viagra) had an 84% increased risk for developing melanoma, even after adjusting for known risk factors, according to the results of a prospective study.
Second Primary Melanoma Risk High Among Melanoma Survivors
In a recent study, survivors of either an invasive or in situ melanoma had about five times the risk for a second primary melanoma compared with the general population.